p.80 抽出テキスト

120. Kim MK, Han K, Kim B, Kim J, Kwon H-S. Effects of exercise initiation and smoking cessation after new-onset type 2 diabetes mellitus on risk of mortality and cardiovascular outcomes. Sci Rep 2022;12:1–9. https://doi.org/10.1038/s41598-022-14603-1 121. Jennings C, Kotseva K, De Bacquer D, Hoes A, de Velasco J, Brusaferro S, et al. Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial. Eur Heart J 2014;35:1411–1420. https://doi.org/10.1093/eurheartj/ehu051 122. Suissa K, Larivière J, Eisenberg MJ, Eberg M, Gore GC, Grad R, et al. Efficacy and safety of smoking cessation interventions in patients with cardiovascular disease: a network meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017;10: e002458. https://doi.org/10.1161/CIRCOUTCOMES.115.002458 123. Gotts JE, Jordt S-E, McConnell R, Tarran R. What are the respiratory effects of e-cigarettes? BMJ 2019;366:l5275. https://doi.org/10.1136/bmj.l5980 124. Skotsimara G, Antonopoulos AS, Oikonomou E, Siasos G, Ioakeimidis N, Tsalamandris S, et al. Cardiovascular effects of electronic cigarettes: a systematic review and meta-analysis. Eur J Prev Cardiol 2019;26:1219–1228. https://doi.org/10.1177/ 2047487319832975 125. Franck C, Filion KB, Eisenberg MJ. Smoking cessation in patients with acute coronary syndrome. Am J Cardiol 2018;121:1105–1111. https://doi.org/10.1016/j.amjcard.2018. 01.017 126. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986. https://doi.org/10.1056/NEJM199309303291401 127. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853. https://doi.org/ 10.1016/S0140-6736(98)07019-6 128. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–2572. https://doi.org/10.1056/NEJMoa0802987 129. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419–430. https://doi. org/10.1016/S0140-6736(10)60576-4 130. Nathan DM, DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014;37:9–16. https://doi.org/10.2337/dc13-2112 131. Writing Group for the DCCT/EDIC Research Group. Coprogression of cardiovascular risk factors in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC study. Diabetes Care 2016;39:1621–1630. https://doi.org/10.2337/dc16-0502 132. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–1589. https://doi.org/10.1056/NEJMoa0806470 133. Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017;5:431–437. https://doi.org/10.1016/S2213-8587(17) 30104-3 134. Turnbull F, Abraira C, Anderson R, Byington R, Chalmers J, Duckworth W, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288–2298. https://doi.org/10.1007/s00125-009-1470-0 135. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375:481–489. https://doi.org/10.1016/S0140-6736(09)61969-3 136. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper M, Colagiuri S, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012;55:636–643. https://doi.org/10. 1007/s00125-011-2404-1 137. International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol 2019;7:385–396. https://doi.org/10.1016/S2213-8587(18)30315-2 138. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42:1593–1603. https:// doi.org/10.2337/dci19-0028 139. Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JC, Green JB, et al. Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype. Diabetes Care 2018;41: 596–603. https://doi.org/10.2337/dc17-1778 140. Standl E, Stevens SR, Lokhnygina Y, Bethel MA, Buse JB, Gustavson SM, et al. Confirming the bidirectional nature of the association between severe hypoglycemic and cardiovascular events in type 2 diabetes: insights from EXSCEL. Diabetes Care 2020;43:643–652. https://doi.org/10.2337/dc19-1079 141. Shahim B, De Bacquer D, De Backer G, Gyberg V, Kotseva K, Mellbin L, et al. The prognostic value of fasting plasma glucose, two-hour postload glucose, and HbA1c in patients with coronary artery disease: a report from EUROASPIRE IV: a survey from the European Society of Cardiology. Diabetes Care 2017;40:1233–1240. https://doi.org/10.2337/dc17-0245 142. Hanssen NM, Kraakman MJ, Flynn MC, Nagareddy PR, Schalkwijk CG, Murphy AJ. Postprandial glucose spikes, an important contributor to cardiovascular disease in diabetes? Front Cardiovasc Med 2020;7:570553. https://doi.org/10.3389/fcvm.2020. 570553 143. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381–386. https://doi.org/10.2337/dc08-1671 144. Kosiborod M. Hyperglycemia in acute coronary syndromes: from mechanisms to prognostic implications. Endocrinol Metab Clin North Am 2018;47:185–202. https:// doi.org/10.1016/j.ecl.2017.11.002 145. Malmberg K, Ryden L, Hamstent A, Herlitz J, Waldenström A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J 1996;17:1337–1344. https://doi.org/10. 1093/oxfordjournals.eurheartj.a015067 146. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26: 650–661. https://doi.org/10.1093/eurheartj/ehi199 147. Caturano A, Galiero R, Pafundi PC, Cesaro A, Vetrano E, Palmiero G, et al. Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence. Diabetes Res Clin Practice 2021;178:108959. https://doi.org/10.1016/j.diabres.2021.108959 148. Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson A-M, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017;376:1407–1418. https://doi.org/10.1056/NEJMoa1608664 149. Stancoven A, McGuire DK. Preventing macrovascular complications in type 2 diabetes mellitus: glucose control and beyond. Am J Cardiol 2007;99:S5–S11. https://doi.org/10. 1016/j.amjcard.2007.04.005 150. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021;384:129–139. https://doi.org/10.1056/NEJMoa2030186 151. Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–657. https://doi.org/10.1056/NEJMoa1611925 152. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357. https:// doi.org/10.1056/NEJMoa1812389 153. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295–2306. https://doi.org/10.1056/NEJMoa1811744 154. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 383:1425–1435. https://doi.org/10.1056/NEJMoa2004967 155. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZ, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6:148–158. https://doi.org/10. 1001/jamacardio.2020.4511 156. Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am College Cardiol 2018;72:3200–3223. https://doi.org/10.1016/j.jacc.2018. 09.020 157. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45(Suppl 1):S144–S174. https://doi.org/10.2337/dc22-S010 158. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373: 2247–2257. https://doi.org/10.1056/NEJMoa1509225 159. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228–1239. https://doi.org/10.1056/NEJMoa1612917 160. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebocontrolled trial. Lancet 2018;392:1519–1529. https://doi.org/10.1016/S0140- 6736(18)32261-X 161. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a doubleblind, randomised placebo-controlled trial. Lancet 2019;394:121–130. https://doi. org/10.1016/S0140-6736(19)31149-3 Downloaded from academic.oup.com/eurheartj/article/44/39/4043/7238227 by guest on 07 October 2026